Compositions and methods for treatment of cardiac diseases
Disclosed herein include microRNA antagonists, therapeutic compositions that include one or more of such microRNA antagonists, and methods of treating and/or ameliorating cardiac diseases and/or muscular dystrophy disorders with the microRNA antagonists. Also included are combination therapies, wherein a therapeutic composition disclosed herein and an additional therapy agent are provided to a subject having or suspected of having cardiac disease and/or muscular dystrophy disorder. In particular, some embodiments disclosed herein relate to compositions and methods for transiently administering a mixture of microRNA antagonists for promoting cardiomyocyte proliferation and cardiac regeneration.
1. A composition, comprising:
(a) at least one miR-99a-5p antagonist comprising a chemically modified nucleotide sequence selected from the group consisting of:
SEQ ID NO: 47 wherein nucleotides 1, 2, 6, 10, 13, 14 and 17-19 of SEQ ID NO: 47 are locked nucleic acids (LNAs),
SEQ ID NO: 48 wherein nucleotides 1, 2, 4, 8, 15, 17 and 18 of SEQ ID NO: 48 are LNAs,
SEQ ID NO: 50 wherein nucleotides 1, 2, 6, 9, 11, 13, 14, 16 and 17 of SEQ ID NO: 50 are LNAs,
SEQ ID NO: 52 wherein nucleotides 1, 2, 6, 10, 13, 15 and 16 of SEQ ID NO: 52 are LNAs, and
SEQ ID NO: 54 wherein nucleotides 1, 2, 6, 9, 11, 12, 14 and 15 of SEQ ID NO: 54 are LNAs;
(b) at least one miR-100-5p antagonist comprising a chemically modified nucleotide sequence selected from the group consisting of:
SEQ ID NO: 46 wherein nucleotides 1, 2, 5, 9, 13, 15 and 17-19 of SEQ ID NO: 46 are LNAs,
SEQ ID NO: 49 wherein nucleotides 1, 2, 6, 9, 13, 15, 17 and 18 of SEQ ID NO: 49 are LNAs,
SEQ ID NO: 51 wherein nucleotides 1, 2, 6, 11, 13 and 15-17 of SEQ ID NO: 51 are LNAs,
SEQ ID NO: 53 wherein nucleotides 1, 2, 6, 10 and 14-16 of SEQ ID NO: 53 are LNAs, and
SEQ ID NO: 55 wherein nucleotides 1, 2, 5, 9-11 and 13-15 of SEQ ID NO: 55 are LNAs;
(c) at least one miR-Let-7a-5p antagonist comprising a chemically modified nucleotide sequence selected from the group consisting of:
SEQ ID NO: 37 wherein nucleotides 1, 2, 6, 10, 13, 14, and 17-19 of SEQ ID NO: 37 are LNAs,
SEQ ID NO: 39 wherein nucleotides 1, 2, 6, 9, 13-15, 17 and 18 of SEQ ID NO: 39 are LNAs,
SEQ ID NO: 40 wherein nucleotides 1, 6, 9, 11, 13 and 17 of SEQ ID NO: 40 are LNAs,
SEQ ID NO: 41 wherein nucleotides 1, 2, 6, 8, 11, 13, and 15-17 of SEQ ID NO: 41 are LNAs,
SEQ ID NO: 42 wherein nucleotides 1, 2, 6, 10, 13, 15 and 16 of SEQ ID NO: 42 are LNAs,
SEQ ID NO: 43 wherein nucleotides 1, 2, 6, 10 and 14-16 of SEQ ID NO: 43 are LNAs,
SEQ ID NO: 44 wherein nucleotides 1, 2, 6, 9, 11 and 15 of SEQ ID NO: 44 are LNAs, and
SEQ ID NO: 45 wherein nucleotides 1, 2, 5, 9-11 and 13-15 of SEQ ID NO: 45 are LNAs; or
(d) at least one miR-Let-7c-5p antagonist comprising a chemically modified sequence selected from the group consisting of:
SEQ ID NO: 36 wherein nucleotides 1, 2, 5, 9, 13, 15, and 17-19 of SEQ ID NO: 36 are LNAs,
SEQ ID NO: 38 wherein nucleotides 1, 2, 7, 12, 14, 15, and 17 of SEQ ID NO: 38 are LNAs,
SEQ ID NO: 40 wherein nucleotides 1, 6, 9, 11, 13 and 17 of SEQ ID NO: 40 are LNAs,
SEQ ID NO: 41 wherein nucleotides 1, 2, 6, 8, 11, 13, and 15-17 of SEQ ID NO: 41 are LNAs,
SEQ ID NO: 42 wherein nucleotides 1, 2, 6, 10, 13, 15 and 16 of SEQ ID NO: 42 are LNAs,
SEQ ID NO: 43 wherein nucleotides 1, 2, 6, 10 and 14-16 of SEQ ID NO: 43 are LNAs,
SEQ ID NO: 44 wherein nucleotides 1, 2, 6, 9, 11 and 15 of SEQ ID NO: 44 are LNAs, and
SEQ ID NO: 45 wherein nucleotides 1, 2, 5, 9-11 and 13-15 of SEQ ID NO: 45 are LNAs;
wherein each of SEQ ID Nos: 36-55 comprises phosphorothioate internucleoside linkages.
2. The composition of claim 1 , comprising:
(a) an miR-99a-5p antagonist comprising one of chemically modified nucleotide sequences of SEQ ID NOs: 47, 48, 50, 52, and 54;
(b) an miR-100-5p antagonist comprising one of chemically modified nucleotide sequences of SEQ ID Nos: 46, 49, 51, 53, and 55;
(c) a miR-Let-7a-5p antagonist comprising one of chemically modified nucleotide sequences of SEQ ID Nos: 37 and 39-45; and
(d) a miR-Let-7c-5p antagonist comprising one of chemically modified sequences of SEQ ID Nos: 36, 38, and 40-45.
3. A pharmaceutical composition, comprising:
a plurality of miR antagonists of claim 2 ; and
a pharmaceutically acceptable excipients, diluents, adjuvants, or stabilizers.
4. A method for promoting cardiac muscle regeneration or for treating a cardiac disease in a subject, comprising administering to a subject in need thereof a pharmaceutical composition of claim 3 .
5. The method of claim 4 , wherein the subject in need thereof is a human subject suffering from a cardiac disease.
6. The method of claim 5 , wherein the cardiac disease is a congenital cardiac disease.
7. The method of claim 5 , wherein the cardiac disease is selected from the group consisting of myocardial infarction, ischemic heart disease, dilated cardiomyopathy, heart failure, ischemic cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, alcoholic cardiomyopathy, viral cardiomyopathy, tachycardia-mediated cardiomyopathy, stress-induced cardiomyopathy, amyloid cardiomyopathy, arrhythmogenic right ventricular dysplasia, left ventricular noncompaction, endocardial fibroelastosis, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, mitral prolapse, pulmonary stenosis, pulmonary regurgitation, tricuspid stenosis, and tricuspid regurgitation.
8. The method of claim 4 , further comprising administering to the subject in need thereof one or more additional therapeutic therapies or agents.
9. The method of claim 8 , wherein at least one of the one or more additional therapeutic therapies or agents comprises Idebenone; Eplerenone; an electrical nerve stimulator; AVI-4658; Ataluren; BMN044/PRO044; CAT-1004; MicroDystrophin AAV Gene Therapy (SGT-001); Galectin-1 Therapy (SB-002); LTBB4 (SB-001); rAAV2.5-CMV-minidystrophin; Glutamine; NFKB inhibitors; Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein); insulin like growth factor-1 (IGF-1); and combinations thereof.
10. The method of claim 8 , wherein the pharmaceutical composition and at least one of the one or more additional therapeutic therapies or agents are administered to the subject sequentially or in rotation.
11. A pharmaceutical composition, comprising:
a composition of claim 1 ; and
a pharmaceutically acceptable excipients, diluents, adjuvants, or stabilizers.
12. A method for promoting cardiac muscle regeneration or for treating a cardiac disease in a subject, comprising administering to a subject in need thereof a pharmaceutical composition of claim 11 .
13. The method of claim 12 , wherein the subject in need thereof is a human subject suffering from a cardiac disease.
14. The method of claim 13 , wherein the cardiac disease is a congenital cardiac disease.
15. The method of claim 13 , wherein the cardiac disease is selected from the group consisting of myocardial infarction, ischemic heart disease, dilated cardiomyopathy, heart failure, ischemic cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, alcoholic cardiomyopathy, viral cardiomyopathy, tachycardia-mediated cardiomyopathy, stress-induced cardiomyopathy, amyloid cardiomyopathy, arrhythmogenic right ventricular dysplasia, left ventricular noncompaction, endocardial fibroelastosis, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, mitral prolapse, pulmonary stenosis, pulmonary regurgitation, tricuspid stenosis, and tricuspid regurgitation.
16. The method of claim 12 , further comprising administering to the subject in need thereof one or more additional therapeutic therapies or agents.
17. The method of claim 16 , wherein at least one of the one or more additional therapeutic therapies or agents comprises Idebenone; Eplerenone; an electrical nerve stimulator; AVI-4658; Ataluren; BMN044/PRO044; CAT-1004; MicroDystrophin AAV Gene Therapy (SGT-001); Galectin-1 Therapy (SB-002); LTBB4 (SB-001); rAAV2.5-CMV-minidystrophin; Glutamine; NFKB inhibitors; Sarcoglycan, delta (35 kDa dystrophin-associated glycoprotein); insulin like growth factor-1 (IGF-1); and combinations thereof.
18. The method of claim 16 , wherein the pharmaceutical composition and at least one of the one or more additional therapeutic therapies or agents are administered to the subject sequentially or in rotation.